MEAGAN HILLHOUSE: Open Payments
NPI 1013484864 · HOUSTON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,462 in 93 payments from 16 companies in 2025. Trend: 2023 $1,630 · 2024 $1,435 · 2025 $1,462
Food & beverage: $1,462
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $229 |
| Lilly USA, LLC | 14 | $211 |
| AstraZeneca Pharmaceuticals LP | 12 | $208 |
| PFIZER INC. | 12 | $204 |
| Amgen Inc. | 11 | $174 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $105 |
| GlaxoSmithKline, LLC. | 5 | $73 |
| Boston Scientific Corporation | 2 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $43 |
| Novo Nordisk Inc | 3 | $43 |
Products named: MOUNJARO, FARXIGA, EVENITY, Kerendia, UBRELVY, NURTEC ODT, JARDIANCE, ELIQUIS.
Industry payments across MS — which companies pay providers there.
